Initially, studies showed that TMB is correlated with the clinical benefit of anti-PD‐1 and anti-CTLA‐4 therapy in several tumor types, including malignant myeloma, non-small cell lung cancer (NSCLC), and various tumors with DNA repair deficits [50]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.